Incannex Healthcare Inc. (IXHL): Depreciation & Amortization
$246.0K
Year ended 2025-06-30
$251.0K
Trailing 12 months to 2026-03-31
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-06-30 | $246.0K | +138.8% | 2025-09-29, From 2024-07-01 |
| 2024-06-30 | $103.0K | +17.0% | 2025-09-29, From 2023-07-01 |
| 2023-06-30 | $88.0K | n/a | 2024-09-30, From 2022-07-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Incannex Healthcare Inc. (IXHL) | 2025-06-30 | $246.0K | +138.8% |
| Actinium Pharmaceuticals, Inc. (ATNM) | 2025-12-31 | $173.0K | -12.2% |
| Connect Biopharma Holdings Ltd (CNTB) | 2025-12-31 | $704.0K | +6.7% |
| Avalo Therapeutics, Inc. (AVTX) | 2025-12-31 | $344.0K | +103.6% |
| Serina Therapeutics, Inc. (SER) | 2025-12-31 | $73.0K | -62.4% |
| HCW Biologics Inc. (HCWB) | 2025-12-31 | $1.04M | -12.0% |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | $146.0K | -16.1% |
| Lyell Immunopharma, Inc. (LYEL) | 2025-12-31 | $11.54M | -41.2% |
| Impact Biomedical Inc. (IBO) | 2025-12-31 | $1.15M | +2.3% |
Compare IXHL, ATNM, CNTB, AVTX side by side · Screen every company in Pharmaceutical Preparations ↗